Update, November 2, 2026. HHS, through the Secretary’s office rather than FDA, announced this policy on October 28, 2026 and published it in the Federal Register on October 30 as the “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances.” It says HHS does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians compounding BPC-157, TB-500, MOTS-c, epitalon, KPV or semax when ten conditions are met, until a final rule decides each peptide. Outsourcing facilities are not covered. The story below describes October 14 and is kept as written. The HHS policy item has the details.
The White House Office of Management and Budget received an FDA document titled “Interim Access Policy for Compounding Using Certain Peptides” for review on October 14, 2026, according to the government’s regulatory review website.
What changed. The review record lists the item as an HHS/FDA “Notice,” not a proposed or final rule, and marks it as not economically significant. Its regulation identifier is RIN 0910-ZD94. Documents like this pass through OMB’s Office of Information and Regulatory Affairs before an agency publishes them.
What it means. The title points to a temporary approach to compounding with some peptides while FDA’s formal bulks-list process continues, three months after the July 2026 advisory committee votes on BPC-157 and five other peptides. Which peptides it covers, what conditions it sets and when it would take effect are unknown, because the text is not public.
If you take this or are considering it. Read the October 28 policy as a decision about enforcement. As of November 2, 2026, none of the six peptides is FDA-approved or on the 503A bulks list, no rule has been proposed, and FDA has not reviewed any compounded product for safety, effectiveness or quality. The notice says the policy creates no rights and is not binding, HHS may revisit it if a safety or quality problem appears, and states can be stricter. The evidence for each peptide is what it was before. Blends such as Wolverine, Glow and Klow fall outside it, because a covered product may hold only one active ingredient. Written comments are open until November 13.
What has not changed. Nothing is in effect yet. None of the peptides from the July votes is approved, and none has been added to the 503A bulks list. Products sold “for research use only” are still not legal to use on people. The FDA status tracker will report the policy when it is published.